User profiles for Y. Kang

Yoon-Koo Kang

- Verified email at amc.seoul.kr - Cited by 62423

Yibin Kang

- Verified email at princeton.edu - Cited by 47096

Yijin Kang (康毅进)

- Verified email at sas.upenn.edu - Cited by 12984

[HTML][HTML] Guidelines and definitions for research on epithelial–mesenchymal transition

…, R Kalluri, Y Kang, Y Khew-Goodall… - … reviews Molecular cell …, 2020 - nature.com
Epithelial–mesenchymal transition (EMT) encompasses dynamic changes in cellular organization
from epithelial to mesenchymal phenotypes, which leads to functional changes in cell …

[HTML][HTML] A review of lithium-ion battery safety concerns: The issues, strategies, and testing standards

Y Chen, Y Kang, Y Zhao, L Wang, J Liu, Y Li… - Journal of Energy …, 2021 - Elsevier
Efficient and reliable energy storage systems are crucial for our modern society. Lithium-ion
batteries (LIBs) with excellent performance are widely used in portable electronics and …

FactSage thermochemical software and databases—recent developments

…, SA Decterov, G Eriksson, K Hack, IH Jung, YB Kang… - Calphad, 2009 - Elsevier
… It should be noted that an increasing partial pressure of H 2 on the y -axis is inverse to
the classical Eh value while an increase in mole fraction of the basic component of the acid–base …

Highly crystalline multimetallic nanoframes with three-dimensional electrocatalytic surfaces

C Chen, Y Kang, Z Huo, Z Zhu, W Huang, HL Xin… - Science, 2014 - science.org
Control of structure at the atomic level can precisely and effectively tune catalytic properties
of materials, enabling enhancement in both activity and durability. We synthesized a highly …

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer …

…, E Kulikov, J Hill, M Lehle, J Rüschoff, YK Kang - The Lancet, 2010 - thelancet.com
… Yoon-Koo Kang … The two principal investigators (Y-JB and EVC) had full access to all
the data in the study and had final responsibility for the decision to submit for publication. …

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo …

AL Cheng, YK Kang, Z Chen, CJ Tsao, S Qin… - The lancet …, 2009 - thelancet.com
Background Most cases of hepatocellular carcinoma occur in the Asia-Pacific region, where
chronic hepatitis B infection is an important aetiological factor. Assessing the efficacy and …

Tumour exosome integrins determine organotropic metastasis

…, K Pantel, AJ Minn, MJ Bissell, BA Garcia, Y Kang… - Nature, 2015 - nature.com
Ever since Stephen Paget’s 1889 hypothesis, metastatic organotropism has remained one
of cancer’s greatest mysteries. Here we demonstrate that exosomes from mouse and human …

Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO …

YK Kang, N Boku, T Satoh, MH Ryu, Y Chao, K Kato… - The Lancet, 2017 - thelancet.com
Background Patients with advanced gastric or gastro-oesophageal junction cancer refractory
to, or intolerant of, two or more previous regimens of chemotherapy have a poor prognosis, …

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

…, SP Choo, J Trojan, TH Welling, T Meyer, YK Kang… - The Lancet, 2017 - thelancet.com
Background For patients with advanced hepatocellular carcinoma, sorafenib is the only
approved drug worldwide, and outcomes remain poor. We aimed to assess the safety and …

[PDF][PDF] Extracellular vesicle and particle biomarkers define multiple human cancers

…, J Bromberg, B Costa-Silva, H Peinado, Y Kang… - Cell, 2020 - cell.com
… ,14 Yibin Kang,19 Benjamin A. Garcia,53 Eileen M. O’Reilly,35 David Kelsen,35 Tanya M. …
MTM, HM, SH, PL, BAG, Y. Kang, and MA performed proteomics analyses. AB-M. performed …